Zacks.com on MSN6d
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease DrugThrough the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...
It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...
After hours: March 21 at 7:45:21 p.m. EDT Loading Chart for AZN ...
After hours: 21 March at 7:45:21 pm GMT-4 Loading Chart for AZN ...
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory ...
Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a significant threat to adults with asthma and COPD. However, research on the virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback